VYNE Therapeutics Inc. (NASDAQ:VYNE) traded today at a new 52-week low of $2.68. This new low was reached on below average trading volume as 131,000 shares traded hands, while the average 30-day volume is approximately 921,000 shares.
VYNE Therapeutics Inc is a biopharmaceutical company which focuses on the development and commercialization of variety of solutions using its proprietary Molecule Stabilizing Technology. The company is developing products which will help improve lives of the patients with dermatological diseases. Its pipeline includes Amzeeq and Zilxi.
In the past 52 weeks, shares of VYNE Therapeutics Inc. have traded between the current low of $2.68 and a high of $13.20 and is now at $2.76.
Potential upside of 98.9% exists for VYNE Therapeutics Inc., based on a current level of $2.76 and analysts’ average consensus price target of $5.49.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer